preference of physicians in prescribing Oral Antidiabetic Treatments (OATs) versus Insulin in Diabetes patients. METHODS: A survey was conducted by CSD, face to face interviews with 200 physicians of several specialties, GPs, diabetologists, endocrinologists who treat at least 30 diabetic patients/month. The sample emerged from formally selected clusters. The sampling strategy was based on stratification of sample. Interviews were conducted from May 12 to June 3, 2009. Results were weighted according to the actual distribution of specialties. RESULTS: The number of patients with type-1 diabetes is approximately 12% and 88% with type-1 diabetes. In DT1 108 different patients from eight countries (CZ, Germany (IQWIG) and Sweden (TLV)) were included in DT1 where patients receive insulin and 83% OATs. Overall, 60% of T2D patients are regulated. Also when adding a third OAT drug 54% of the patients will delay the use of insulin. Unmet needs mentioned spontaneously by physicians are: a) poor compliance to treatment; b) lack of control to diet; and c) high cost of co-payment for medicines. CONCLUSIONS: Based on the results of the present study, physicians use insulins for DT1 patients and they prefer OATs for TIIID. The economic burden of TIIID patients is heavy due to high co-payment rate, which might be linked to poorly regulated patients leading to higher incidence of diabetes-related complications.

**PDB71 GLYCAEMIC AND CHOLESTEROL CONTROL OF TYPE 2 DIABETIC PATIENTS ATTENDING SPECIALIST OUTPATIENT CLINICS IN SINGAPORE**

Lim BK1, Toh MPH2, Cheah T3, Sam Chee F4, Jong M1, Chioh SB5

1National Healthcare Group, Singapore, Singapore, 2Alexandra Hospital, Singapore, Singapore, 3Tan Tock Seng Hospital, Singapore, Singapore, 4National University Hospital, Singapore, Singapore

OBJECTIVES: The specialist outpatient clinics (SOCs) of the 3 acute hospitals of the National Healthcare Group (NHG) in Singapore treat over 11,000 patients with diabetes mellitus. This paper studies the glycaemic and cholesterol control of type 2 diabetic patients at these SOCs. METHODS: This study was conducted in four capital cities of Greece. The sampling method was based on stratified random sampling. Interviews were conducted from May 12 to June 3, 2009. Results were assessed for date, type (e.g., single drug versus class review) and scope (e.g., different conditions) of T2D patients who attended the hospital SOCs in Jan 2009 for treatment of diabetes. These patients had been on follow-up at the same clinic for at least 12 months. The latest glyced haemoglobin (HbA1c) and LDL-cholesterol (LDL-c) results were compared by age, gender and ethnic group. Data was extracted from the NHG Diabetes Registry (CDMS). RESULTS: There were 3,420 T2D patients with more females (51%) and disproportionately more Indians (14.1%) and fewer Chinese (66.3%) than the general population. The mean ages of male and female were 61.8 and 64.9 years respectively. The proportion of patients with ‘optimal’ HbA1c (7% and LDL-c (<2.6 mmol/L) control increased with age. For HbA1c, 13% of patients <35 years had “optimal” control (mean 8.96%, 95%CI 8.42-9.5%) increasing to 61% for patients 85+ years (mean 7.04%, 95%CI 6.79-7.28%). Similarly for LDL-c, 41% of patients <35 years had “optimal” control (mean 2.92 mmol/L, 95%CI 2.63-3.21 mmol/L), increasing to 74% for patients 85+ years (mean 2.28 mmol/L, 95%CI 2.14-2.41 mmol/L). Chinese had better HbA1c and LDL-c control whilst Malay and Indian were poorest for LDL-c and HbA1c respectively. There was no gender difference. CONCLUSIONS: The control of HbA1c and LDL-c among T2D patients improved with age. Younger patients and the Malay and Indian subgroups had greater potential to achieve “optimal” glycemic and cholesterol control and reduce the risk of developing micro- and macro-vascular complications over time. While the older patients achieved better HbA1c control than younger ones, clinicians should remain mindful of side effects such as hypoglycaemia among those with very tight glycaemic control.

**PDB72 QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA**

Je MW1, Lee WJ2, Noh JH2, Choi Y3, Song HK4

1University of Seoul, Seoul, South Korea, 2Yonsei University Iian Paik Hospital, Iian, Gyonggi-Do, South Korea, 3institute-ventis Korea, Seoul, South Korea, 4Kunkuk University Hospital, Seoul, South Korea

OBJECTIVES: This study was conducted to estimate quality adjusted life years (QALYs) loss due to diabetes in type 2 diabetic patients of South Korea. METHODS: In order to obtain QALYs loss due to morbidity of type 2 diabetes (T2D), we firstly estimated utility weight difference between T2D patients and non-diabetic subjects by sex and age groups. We consecutively recruited T2D patients aged 20 or over who visited three university hospitals in Seoul and Iian from October 2007 to January 2008 and non-diabetic subjects who took a medical examination from June 2008 to Jan 2009 in same hospitals. Utility weight differences on sex and age groups were calculated using the EuroQol, EQ-5D and Korean valuation set, and then QALY losses was estimated using the utilities and the number of T2D patients in 2003 reported by the Korean Diabetes Basic Statistics Study. QALY losses due to T2D mortality correlated to life expectancy of the death caused T2D from the life table and the Korean Death Certificate in 2003 multiplied by utility weights of healthy people by sex and age groups from the 3rd Korea National Health and Nutrition Examination Survey 2007-2008. We added a discount rate as 5%. RESULTS: Total 1,072 T2D patients and 387 non-diabetic subjects participated in this survey. Maximum difference between T2D patients and non-diabetic subjects was 0.0048 and minimum difference was 0.0038 by subgroups. QALY loss estimates due to T2D morbidity were about 35,125 QALYs in male and 50,613 QALYs in female in 2007. Total QALYs brought about 58,186 QALYs in male and 49,432 QALYs in female considering the discount rate. Therefore, total QALY loss was estimated as 193,336 QALYs annually. CONCLUSIONS: The results suggest that QALY loss estimates caused by T2D was 4.0 QALYs/1000 persons in South Korea at 2003.

**PDB73 ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES**

Adalsteinsson E1, Jensen RCP2, Mandrich T1, Helem M1

1Novo Nordisk A/S, Bagsværd, Denmark, 2Copenhagen University, Copenhagen, Denmark, 3University Claude Bernard Lyon, Lyon, France, 4Novo Nordisk A/S, baguvar, Denmark

OBJECTIVES: To map factors that influence HTA-agencies in their Health Technology Assessments (HTA) on type 2 diabetes agents in the UK (NICE), Scotland (SMC), The Netherlands (IQWIG) and Sweden (TLV). METHODS: To retrieve the HTA reports, a search was executed using the agencies websites with the following keywords: pioglitazone, rosiglitazone, sitagliptin, vildagliptin, exenatide, glargine, detemir, aspart, glulisine and lopido. If a report contained several drugs each drug was counted separately allowing a decision could involve more than one parameter. Factor parameters were clustered in three categories: efficacy, safety and health economic where each parameter could contain multiple parameters. Overall recommendation was classified in three categories: recommended restricted and not recommended in relation to indication based on marketing authorisation. RESULTS: 35 reports were identified with 49 assessments. Twelve assessments lead to recommendation (24%), 23 to restricted recommendation (47%) and fourteen to no recommendation (29%). Reasons for recommending a treatment contained in 83% of cases one or more arguments related to efficacy, 33% to safety, and 66% to health economic aspects of drugs. Reasons for restricted recommendation were 70%, 39%, and 60%, and for not recommended were 100%, 57% and 21% respectively. Within each decision parameter the most common reason for restricting the market authorization indication was related to the drug not being cost-effective (57%). The most common reason for not recommending a drug was lack of long term data on efficacy (86%). CONCLUSIONS: Despite that large variations in results between agencies were observed, data demonstrating efficacy of the drug appeared to be the most important factor in getting a recommendation for type 2 diabetes treatment. A high incremental cost-effectiveness ratio was likely to lead to restrictions in indication (NICE, SMC and TLV) whereas lack of long term data could lead to the drug not being recommended (IQWIG and CVZ).

**PDB74 ETHICAL DILEMMA OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES—A REVIEW OF THE LITERATURE**

Claude Bernard Lyon, Lyon, France, 4Novo Nordisk A/S, bagsværd, Denmark

OBJECTIVES: There is increasing focus on the ethical analysis in Health Technology Assessments (HTA). Due to the exponential increase of the number of diabetes cases, there is an urgent health concern. We therefore systematically reviewed published articles describing the ethical aspects of pharmacological treatment and self management of diabetes. METHODS: PubMed was searched from inception to 2009 using the following combinations of keywords: ethics AND diabetes NOT screening NOT transplant. Articles were initially screened for relevance by reading title and abstract. If deemed appropriate, by two independent reviewers, full copies of the remaining articles were retrieved for further review. RESULTS: Out of 336 articles, only six studies were deemed appropriate. The main reason for this high level of rejected articles was that the majority of identical articles commented on the ethical approval in connection to conducting clinical studies rather than on the ethical aspects of implementing and using the specific technology. One study described the ethical concern related to the costly late complications of diabetes compared to preventing late complications by prescribing and reimbursing insulin. Other ethical issues concerned self management and the transferal of responsibility from physician to patient and the patient’s capabilities for self management. For people with impaired glucose tolerance there were also ethical issues related to initiating a preventive pharmacological treatment of the “otherwise well”. Lastly, there is an ethical issue between the normative golden standard for a healthy and moral lifestyle and a culture of self that values authenticity and originality. CONCLUSIONS: Due to the escalating prevalence of diabetes and emphasis on ethical analysis in HTAs, both payers and the industry needs to get a better understanding of the ethical aspects of self management and pharmacological treatment of diabetes. More research should be allocated towards investigating the ethical aspects of self management and pharmacological treatment of diabetes.

**PDB75 APPLICATION OF HTA TO ANTI DIABETIC DRUG FORMULARY DECISIONS**

Andrejkov M, Wiebinga C

Quintiles Consulting, Hoofddorp, The Ntherlands

OBJECTIVES: To compare Health Technology Assessments (HTAs) and reimbursements decisions of a novel antidiabetic drug class, by health care agencies worldwide. METHODS: We conducted manual searches of 54 health care agencies’ websites from January 2008 to May 2009. HTAs regarding diabetes were collected and each was assessed for date, type (e.g., single drug versus class review) and scope (e.g., medicine name). Using a standardized set of categorical criteria, we investigated recommendations, as well as presence of supporting evidence (e.g., reported outcome measures, information sources, and key decision drivers). RESULTS: A total of 21 completed diabetes assessments were assessed. Data were retrieved from 9 agencies in 9 countries. The agencies published 21 assessments on diabetes during the review period, including 3 clinical guidelines, 9 single drug appraisals and 8 class reviews. Of

---

*Paris Abstracts*
the 6 agencies (9 publications) that evaluated DPP-4 inhibitors, 2 recommended the drug not be listed or funded (CADTH, AHTAPol) and 4 recommended restricted use (PBAC, SMC, CVZ and NICE). The most common reason for agency’s disinclination for listing/funding was insufficient information on the effectiveness and cost-effectiveness of the drug in the specified patient population. More than 100 HTAs on OGLD, the endocrine nutritional and metabolic therapeutic area, approximately half of them (49 projects) concern diabetes, 21 of which evaluate pharmacological treatment of diabetes (8 countries, 11 agencies). CONCLUSIONS: Diabetes prevalence is on the rise, attracting attention from health care agencies. Despite health care data sources variable outcomes suggest to us that agencies are applying different weightings in their assessment process. The apparent failure to demonstrate effectiveness in specified populations suggests late segmentation by manufacturers and insufficient insurancerequiring data. This is often due to late payer requests for such analyses motivated by financial considerations. Early segmentation and engagement with payers is thus critical for HTA success.

ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS

Kais C1, Jensen RCG2, Adlustenjon E3
1Center for Clinical and Experimental Research, Copenhagen, Denmark, 2Novo Nordisk A/S, Bagsværd, Denmark
OBJECTIVES: Health Technology Assessment (HTA) is mostly known for its health economic properties even though it is a multidisciplinary form of policy research examining long-term consequences of the application of a health technology. There is an increased focus on ethical analyses on HTA. A descriptive analysis was conducted on diabetes HTA reports describing ethical analyses. METHODS: The NHS Centre for Reviews and Dissemination HTA database (http://www.crd.york.ac.uk/credweb) was searched (1991–2009) using the keyword ‘diabetes’. HTA reports in English with longer duration diabetes assessment were included as an indication of type of ethical analyses. RESULTS: Of 263 HTA reports identified in the initial search, 60 met the inclusion criteria. 4 reports included a type of ethical analysis (2 from CADTH, Canada; 1 from AHTA, Australia and 1 from NZHTA, New Zealand). CADTH conducted ethical analyses on short- and long-acting insulin analogues respectively, concluding that both types of insulin analogues did not exacerbate—might even better—the psychosocial issues of diabetes, however more quality-of-life evidence were needed. In AHTA’s assessment of a continuous glucose monitoring device and access issues related to costs, and that the device could not replace standard of care, but should be used as an adjunct. NZHTA’s assessment of continuous glucose monitoring devices was also related to equity concerns, concluding a need for more affordable devices. CONCLUSIONS: Ethical analyses motivated by financial considerations. Early segmentation and engagement with payers is thus critical for HTA success.

BASELINE CHARACTERISTICS OF PATIENTS BEGINNING BASAL, BASAL PLUS SHORT-ACTING, SHORT-ACTING OR PREMIX INSULIN. DATA FROM THE CREDIT STUDY

Home P1, Blonde L2, Marre M3, Admane K4, Vespasiani G5
1Newcastle University, Newcastle upon Tyne, UK, 2Ochsner Medical Center, New Orleans, LA, USA, 3Université Paris, INSERM U695, Paris, France, 4‘Sanofi-Aventis, Paris, France, 5‘Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy.
OBJECTIVES: The ongoing Cardiovascular (CV) Risk Evaluation in people with Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is assessing the effect of insulin on the risk of vascular events, which can be reduced via long-term glycaemic control. METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North America, Europe and Asia. It includes 3031 people with T2DM who had recently started basal and/or short-acting insulin, premix insulin or another insulin type. This analysis examines and compares the characteristics between groups starting basal (n = 1563), basal + short-acting (n = 444), short-acting (n = 221), premixed (n = 700) or another (n = 103) insulin. RESULTS: Demographic and diabetes characteristics were reasonably balanced between the insulin groups, although those receiving basal plus short-acting insulin or premix had a trend to a higher baseline HbA1c levels vs other insulin types (basal, 9.2 ± 1.8%; basal + short-acting, 9.4 ± 2.0%; premix, 9.9 ± 2.0%; other, 9.1 ± 2.0%). While the majority had previously used oral glucose lowering drugs (OGLDs) (basal, 97%, basal + short-acting, 83%; short-acting, 83%; premix, 94%; other, 83%), differences in the numbers continuing OGLDs when beginning insulin were found. Continued use of OGLDs was highest with basal insulin (89%) versus the other insulin (basal + short-acting, 86%; short-acting, 45%; premix, 62%; other, 34%). However, the distribution of types of OGLD used before insulin was similar between the groups. There are no clear patterns in CV risk profile by insulin type. Previous diagnosis of hypertension (basal, 71%; basal + short-acting, 65%; short-acting, 77%; premixed, 66%; other, 72%), family history of CV disease (basal, 29%; basal + short-acting, 25%; short-acting, 21%; premix, 23%; other, 14%) and body mass index tended to be lower in the short-acting insulin group. However, triglyceride levels were lower in the short-acting and ‘other’ insulin groups vs premix, basal and basal plus short-acting groups. CONCLUSIONS: People starting different insulin have somewhat different clinical characteristics, which may confound attempts to compare future vascular outcomes between regimens.

DIFFERENCES IN THE CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES STARTING INSULIN IN THE NORTH, SOUTH AND EAST OF EUROPE: DATA FROM THE CREDIT STUDY

Marre M1, Home P2, Vespasiani G3, Admane K4, Blonde L5
1University Paris, INSERM U695, Paris, France, 2University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 3‘Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy, 4‘Sanofi-Aventis, Paris, France, 5‘Ochsner Medical Center, New Orleans, LA, USA
OBJECTIVES: Maintaining long-term glycaemic control with insulin therapy can reduce the risk of vascular events associated with Type-2 diabetes mellitus (T2DM). The Cardiovascular (CV) Risk Evaluation in people with T2DM on Insulin Therapy (CREDIT) study is an ongoing 4-year, non-interventional trial in 314 centres across North America, Europe and Asia. METHODS: People with T2DM who recently started insulin were included. Here we report variation in baseline characteristics of participants in eastern vs northern vs southern Europe. RESULTS: Marked differences in participant characteristics were found between eastern Europe (n = 735), northern (n = 460) and southern Europe (n = 647), including proportion of males (25 ± 61.5%, diabetes duration (8.5 ± 13 ± 13 ± 9 years), age (35 ± 8 vs. 63.5 ± 11 vs. 63 ± 11 years) and HbA1c (9.7 ± 1.9 vs. 9.1 ± 2.0 vs. 9.3 ± 1.9%). Combinations of oral glucose-lowering drugs were common before insulin; sulfonylureas were dose-reduced or withdrawn elsewhere. Overall, 22% of patients were using glucose medications before insulin initiation, most commonly ARBs. People in eastern Europe had a greater family history of CV disease, were less physically active, but were not more obese (BMI: 30.7 ± 5 vs. 31.5 ± 6.3 vs. 29.6 ± 5.9 kg/m²). Rates of admission were lowest in southern Europe, HLD cholesterol was lowest in southern and in northern Europe and in females was highest in eastern Europe. LDL cholesterol was highest in southern Europe. Total cholesterol levels were lowest, but triglyceride levels were highest in northern Europe. Smoking was less prevalent in eastern Europe. Most people began with a basal insulin regimen (63 ± 63 vs. 6%; more people used meal-time insulins in eastern Europe (19 ± 11 vs. 17%) and pre-mixes in northern Europe (22 vs. 8 ± 13%). CONCLUSIONS: Baseline characteristics of people starting insulin reveals some striking differences between European regions; how these translate into CV events as the study progresses will be of interest.

DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COME WITH THE POPULATION IN THE CREDIT STUDY?

Vespasiani G1, Marre M2, Blonde L3, Admane K4, Home P5
1‘Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy, 2Université Paris, INSERM U695, Paris, France, 3‘Sanofi-Aventis, Paris, France, 4University of Newcastle upon Tyne, Newcastle upon Tyne, UK
OBJECTIVES: The Cardiovascular Risk Evaluation in people with Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is evaluating the effect of insulin on the risk of vascular events, which can be reduced via long-term glycaemic control. METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North America, Europe and Asia. It includes 3031 people with T2DM who had recently started basal, short-acting or premix insulin, over half of whom received basal insulin alone (n = 1563). This analysis examines the baseline characteristics of the subgroup initiating basal insulin after oral failure and compares them with those of the wider CREDIT population. RESULTS: The mean starting dose of basal insulin was 14.7 ± 2.0 U/day, administered once daily in 86% of participants. Of these, 61% took their injection at bedtime, 21% at breakfast, 17% at dinner and 1% at lunch. Over 90% used pen devices, split equally between disposable (46%) and reusable devices (45%). Demographic and clinical characteristics, including macrovascular disease and cardiovascular risk profiles, were broadly similar between the basal insulin subgroup and the overall group of participants (basal insulin subgroup vs total population: males, 48 ± 51%; age, 62.2 ± 11 ± 13 ± 10 years; T2DM duration, 10 ± 7 ± 11 ± 8 years; HbA1c, 9.2 ± 1.8 vs. 9.5 ± 2.0%: prior use of oral glucose lowering drugs (OGLDs), 97 vs 93%): Use of OGLDs with insulin tended to be higher in the basal insulin subgroup than in the total group of patients (any OGLD, 89 vs. 70%; biguanides, 64 vs. 50%, sulfonylureas, 63 vs. 43%). CONCLUSIONS: The one notable difference between the groups was that those who began basal insulin alone were more heavily treated with OGLDs beforehand than in the overall population, most commonly biguanides and sulfonylureas. This suggests that they required lower insulin doses to achieve glycemic management than people starting on other types of insulin.

MEASURING GLYCOSYLATED HAEMOGLOBIN LEVELS IN PATIENTS WITH DIABETES: IMPACT OF LOWER QOF TARGETS ON ACHIEVEMENT OF CLINICAL INDICATORS AND QOF POINTS

Knigge S1
1Pension Zenica UK Ltd, Luton, UK
OBJECTIVES: The 2008/09 Quality and Outcomes Framework (QOF) indicators for measuring glycosylated haemoglobin (HbA1c levels) are DM20 and DM07, which measure percentage of diabetic patients with HbA1c of either 7.5 or 10 or less respectively. New QOF clinical indicators have been agreed for 2009/10: DM23